PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33520633-0	2021	In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex.	Enalaprilat	46-57	angiotensin converting enzyme 2	Homo sapiens	134-165	
33520633-7	2021	Using umbrella sampling molecular dynamics simulations, the binding energy of SP with ACE2 (-29.58 kcal/mol) without ligands, and in complex with amprenavir (-20.13 kcal/mol), enalaprilat (-23.84 kcal/mol), and plerixafor (-19.72 kcal/mol) were calculated.	Enalaprilat	176-187	angiotensin converting enzyme 2	Homo sapiens	86-90	
33218024-6	2020	Among them, enalaprilat, an ACE inhibitor, showed a Kd value of 1.5 nM against the ACE2.	Enalaprilat	12-23	angiotensin converting enzyme 2	Homo sapiens	83-87